Literature DB >> 9122101

Ursodeoxycholic acid in the treatment of liver diseases.

S Saksena1, R K Tandon.   

Abstract

Ursodeoxycholic acid is a dihydroxy bile acid with a rapidly expanding spectrum of usage in acute and chronic liver diseases. The various mechanisms of action of this hydrophilic bile acid include direct cytoprotection, detergent action on dysfunctional microtubules, immunomodulation and induction of hypercholeresis. Its efficacy in primary biliary cirrhosis and primary sclerosing cholangitis as an adjunct to medical therapy has been well established. Newer indications include its use in the management of chronic hepatitis, cirrhosis, post liver transplant rejection, graft-versus-host disease and acute viral hepatitis, where it not only relieves symptoms of cholestasis but also arrests ongoing hepatocyte necrosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9122101      PMCID: PMC2431224          DOI: 10.1136/pgmj.73.856.75

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  56 in total

1.  Modulation of low density lipoprotein receptor activity by bile acids: differential effects of chenodeoxycholic and ursodeoxycholic acids in the hamster.

Authors:  M Malavolti; H Fromm; S Ceryak; I M Roberts
Journal:  J Lipid Res       Date:  1987-11       Impact factor: 5.922

2.  Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid.

Authors:  Y Calmus; P Gane; P Rouger; R Poupon
Journal:  Hepatology       Date:  1990-01       Impact factor: 17.425

3.  Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial.

Authors:  S Bellentani; G Tabarroni; T Barchi; I Ferretti; N Fratti; E Villa; F Manenti
Journal:  J Hepatol       Date:  1989-01       Impact factor: 25.083

4.  Caloric content of a meal affects duration but not contractile pattern of duodenal motility in man.

Authors:  A Ouyang; A G Sunshine; J C Reynolds
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

5.  Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment.

Authors:  A Stiehl; R Raedsch; G Rudolph
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

6.  Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial.

Authors:  U Leuschner; H Fischer; W Kurtz; S Güldütuna; K Hübner; A Hellstern; M Gatzen; M Leuschner
Journal:  Gastroenterology       Date:  1989-11       Impact factor: 22.682

7.  Cirrhosis as a consequence of graft-versus-host disease.

Authors:  A B Knapp; J M Crawford; J M Rappeport; J L Gollan
Journal:  Gastroenterology       Date:  1987-02       Impact factor: 22.682

8.  Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents.

Authors:  Y B Yoon; L R Hagey; A F Hofmann; D Gurantz; E L Michelotti; J H Steinbach
Journal:  Gastroenterology       Date:  1986-04       Impact factor: 22.682

9.  The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man.

Authors:  K Knyrim; N Vakil; R Pfab; M Classen
Journal:  Hepatology       Date:  1989-08       Impact factor: 17.425

10.  Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man.

Authors:  M Parquet; E H Metman; A Raizman; J C Rambaud; N Berthaux; R Infante
Journal:  Eur J Clin Invest       Date:  1985-08       Impact factor: 4.686

View more
  9 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

Review 3.  Ursodeoxycholic acid for primary biliary cirrhosis.

Authors:  Jelena S Rudic; Goran Poropat; Miodrag N Krstic; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease.

Authors:  P Ljubuncic; Z Tanne; A Bomzon
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

5.  Effect of Ursodeoxycholic Acid on the Biodistribution and Excretion of Technetium-99m Radiopharmaceuticals in Rat: A Potential Image Quality Enhancer.

Authors:  Yeon Hee Han; Hwan Jeong Jeong; Eun Mi Kim; Fatima Boud; Seok Tae Lim; Sun Young Lee; Myung Hee Sohn
Journal:  Yonsei Med J       Date:  2021-06       Impact factor: 2.759

6.  Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.

Authors:  Torsten Diesinger; Vyacheslav Buko; Alfred Lautwein; Radovan Dvorsky; Elena Belonovskaya; Oksana Lukivskaya; Elena Naruta; Siarhei Kirko; Viktor Andreev; Dominik Buckert; Sebastian Bergler; Christian Renz; Edith Schneider; Florian Kuchenbauer; Mukesh Kumar; Cagatay Günes; Berthold Büchele; Thomas Simmet; Dieter Müller-Enoch; Thomas Wirth; Thomas Haehner
Journal:  PLoS One       Date:  2020-07-23       Impact factor: 3.240

7.  Bile acids in treatment of ocular disease.

Authors:  Jeffrey H Boatright; John M Nickerson; Anisha G Moring; Machelle T Pardue
Journal:  J Ocul Biol Dis Infor       Date:  2009-08-27

8.  Efficacy and Safety of "URSA Complex" in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

Authors:  Kwang-Min Kim; Moon-Jong Kim; Sang-Wook Song; Doo-Yeoun Cho; Kyung-Chae Park; Sung-Won Yang; Young-Sang Kim; Kyung-Soo Kim
Journal:  Chin Med J (Engl)       Date:  2016-01-20       Impact factor: 2.628

9.  Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial.

Authors:  B Oh; W S Choi; S B Park; B Cho; Y J Yang; E S Lee; J H Lee
Journal:  Int J Clin Pract       Date:  2016-03-20       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.